Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2020-04-20 Director's Dealing
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard template for 'notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It identifies a specific individual (Ivan M. Møller), their position (SVP), the issuer (Zealand Pharma A/S), and details of a transaction involving warrants. This is a classic insider dealing/director's dealing notification.
2020-04-20 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for the notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMRs). It explicitly identifies the individual (CFO Matthew Dallas), the issuer (Zealand Pharma A/S), and details a transaction involving warrants. This is a classic 'Director's Dealing' or 'PDMR Notification' filing.
2020-04-20 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard template for 'notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It identifies a specific executive (Adam Steensberg) and details a transaction involving warrants (grant of warrants). This is a classic insider dealing notification, which corresponds to the 'Director's Dealing' category.
2020-04-20 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is titled 'Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons'. This is a standard disclosure for insider trading or director dealings, which corresponds to the 'Director's Dealing' category.
2020-04-20 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is a formal announcement regarding transactions in company shares by persons discharging managerial responsibilities (PDMRs). This specific type of disclosure is classified as a Director's Dealing (DIRS) report, as it pertains to insider trading/share transactions by management.
2020-04-20 English
Earnings Release 2019
Earnings Release Classification · 95% confidence The document is a press release dated April 15, 2020, announcing clinical trial results regarding the use of regular human insulin with the V-Go device. It highlights key findings (non-inferiority, cost savings) and mentions where the full abstract and health economic outcomes will be published (Journal of the Endocrine Society, Journal of Managed Care & Specialty Pharmacy supplement). This structure—a company issuing a formal announcement detailing recent performance, clinical data, or business updates, often referencing where the detailed report resides—is characteristic of an Earnings Release (ER) or a general press release summarizing significant news. Since it focuses on clinical trial results and health economics rather than quarterly financial figures (which would suggest ER or IR), and it is a direct announcement of results rather than a notice to publish a report (RPA), it best fits the 'Earnings Release' category as a primary announcement of period-specific operational/research outcomes, or potentially 'Regulatory Filings' (RNS) if it were less specific. Given the detailed nature of the results announcement, ER is the most appropriate fit among the specific options, as these types of clinical updates often accompany or substitute for formal earnings reporting in biotech/pharma. FY 2019
2020-04-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.